← FDA DRUG APPROVALS

FDA NDA · NDA209805

STEGLUJAN

ertugliflozin and sitagliptin

Sponsor: MSD SUB MERCK

APPLICATION
NDA209805
TYPE
NDA
ORIGINAL APPROVAL
2017-12-19
LATEST ACTION
2026-06-03
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

STEGLUJAN · ReferencePrescription
ERTUGLIFLOZIN 15MG, SITAGLIPTIN PHOSPHATE EQ 100MG BASE · TABLET · ORAL
STEGLUJAN · ReferencePrescription
ERTUGLIFLOZIN 5MG, SITAGLIPTIN PHOSPHATE EQ 100MG BASE · TABLET · ORAL

Approval history

2026-06-03Labeling · Supplement 22 · standard — Letter ↗AP
2024-12-20Labeling · Supplement 17 · standard — Letter ↗AP
2023-09-12Labeling · Supplement 16 · standard — Letter ↗AP
2022-10-13Labeling · Supplement 12 · 901 required — Letter ↗AP
2022-06-21Labeling · Supplement 11 · standard — Letter ↗AP
2022-03-02Labeling · Supplement 10 · standard — Letter ↗AP
2021-09-17Efficacy · Supplement 8 · standard — Label ↗AP
2020-01-24Labeling · Supplement 6 · 901 required — Label ↗AP
2019-07-01Labeling · Supplement 5 · 901 required — Letter ↗AP
2018-10-26Labeling · Supplement 4 · 901 required — Label ↗AP
2018-03-06Labeling · Supplement 1 · standard — Label ↗AP
2017-12-19Type 4 - New Combination · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →